Plasmodium Falciparum Blood Stage Inhibitor Compounds for Malaria Treatment
Summary
USPTO published patent application US20260097046A1 disclosing compounds that inhibit Plasmodium falciparum asexual blood stage parasites for malaria treatment. The compounds exhibit sub-millimolar potency against intraerythrocytic stages and are soluble for oral administration. Inventors include Alicia N. Wagner, Roger Trombley, and 8 others. Application filed December 12, 2025.
What changed
USPTO published patent application US20260097046A1 for antimalarial compounds. The application discloses novel compounds inhibiting Plasmodium falciparum asexual blood stage parasites, with sub-millimolar potency and aqueous solubility at pH 7.4 suitable for oral administration.
Affected parties in the pharmaceutical and biotechnology sectors should monitor this application for potential freedom-to-operate implications in malaria drug development. The broad CPC classifications spanning multiple heterocyclic compound classes (C07D) and therapeutic uses (A61P 33/06) indicate wide claim scope that may affect similar compound development programs.
What to do next
- Monitor for patent grant status
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS
Application US20260097046A1 Kind: A1 Apr 09, 2026
Inventors
Alicia N. WAGNER, Roger TROMBLEY, Maris E. PODGURSKI, Jacqueline R. SMITH, Meng CUI, Adriana A. MARIN, Steven P. MAHER, Dennis E. KYLE, Roman MANETSCH, Anthony A. RUBERTO
Abstract
In one aspect, the disclosure relates to compounds that inhibit Plasmodium falciparum asexual blood stage parasites (PfABS) In one aspect, the compounds exhibit sub-millimolar potency against the intraerythrocytic stages of Plasmodium falciparum and other Plasmodium species. In another aspect, the compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration to patients. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the same, and methods of treating or preventing malaria using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
CPC Classifications
A61K 31/551 A61K 31/4164 A61K 31/4192 A61K 31/4196 A61K 31/421 A61K 31/4245 A61K 31/426 A61K 31/427 A61K 31/429 A61K 31/4418 A61K 31/4439 A61K 31/454 A61K 31/455 A61K 31/496 A61K 31/497 A61K 31/498 A61K 31/501 A61K 31/506 A61K 31/536 A61K 31/5377 A61K 31/538 A61P 33/06 C07B 59/002 C07D 213/50 C07D 213/81 C07D 233/90 C07D 237/24 C07D 239/28 C07D 241/24 C07D 249/04 C07D 249/10 C07D 263/34 C07D 271/10 C07D 277/56 C07D 401/04 C07D 401/06 C07D 401/12 C07D 403/04 C07D 403/06 C07D 405/12 C07D 413/04 C07D 413/06 C07D 413/12 C07D 417/12 C07D 513/04
Filing Date
2025-12-12
Application No.
19417523
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.